# Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

> **NCT01232595** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 109 (actual)

## Conditions studied

- Moderate Clostridium Difficile Infection

## Interventions

- **DRUG:** LFF571
- **DRUG:** Vancomycin (POC)

## Key facts

- **NCT ID:** NCT01232595
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01232595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01232595, "Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01232595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*